Dr. Michael Morris, MD, MS

Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI, is a visionary physician-scientist renowned for his contributions to nuclear medicine, diagnostic radiology, and clinical informatics. As a co-founder of United Theranostics and the Medical Director Glen Burnie, Maryland, Dr. Morris has been instrumental in advancing radiopharmaceutical therapies and molecular imaging techniques, particularly in the treatment of prostate cancer and neuroendocrine tumors.
More Details

Educational Background and Certifications

Dr. Morris holds a Doctor of Medicine (MD) and a Master of Science (MS) degree. He is board-certified by the American Board of Radiology (DABR), the American Board of Nuclear Medicine (DABNM), and holds a Diplomate in Clinical Informatics (DCI). These certifications underscore his multidisciplinary expertise, integrating advanced imaging, therapeutic interventions, and informatics to enhance patient care.

Clinical Leadership at United Theranostics

At United Theranostics, Dr. Morris has been treating cancer patients with radiopharmaceutical therapy for nearly a decade. His dedication to excellence and patient-centered care has made the Chesapeake Center a preferred destination for patients in the Baltimore and Washington regions. Under his leadership, the center has become a hub for cutting-edge treatments, offering therapies like Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for prostate cancer patients.

Research Contributions and Clinical Trials

Dr. Morris has served as the Principal Investigator on numerous FDA clinical trials across all phases, focusing on the development and implementation of novel radiopharmaceutical therapies and molecular imaging techniques. His research interests include targeted radiopharmaceutical therapy, dosimetry, PET imaging, and quantification, with a particular emphasis on neuroendocrine tumors and prostate cancer Michael A. Morris, MD, MS

He has been actively involved in exploring actinium-225 in PSMA-targeted therapy for prostate cancer, discussing its potential in recent presentations. Additionally, Dr. Morris has contributed to discussions on the future of PSMA-targeted therapies in advanced prostate cancer, highlighting the evolving landscape of precision medicine. The Future of PSMA-Targeted Therapies in APC: Part 1 | GU Oncology Now

Academic and Editorial Roles

Beyond his clinical and research endeavors, Dr. Morris is an adjunct faculty member at the University of Miami and the University of Maryland. He has authored over 60 peer-reviewed publications, contributing significantly to the fields of nuclear medicine, diagnostic radiology, and clinical informatics. His work has been cited extensively, reflecting his influence on contemporary medical practices and research methodologies. Michael A Morris, MD, MS, DABR, DABNM, DCI‬ – Google Scholar‬‬‬‬‬‬‬

Professional Affiliations and Recognitions

Dr. Morris is a Diplomate of the American Board of Radiology and the American Board of Nuclear Medicine. His commitment to integrating clinical informatics into medical practice has earned him recognition as a leader in the field. He has been featured in various professional platforms, including UroToday and GU Oncology Now, where he has shared insights on PSMA-targeted therapies and the future of prostate cancer treatment.

Contact Information

(11) Michael Morris, MD, MS, DABR, DABNM, DCI | LinkedIn

Dr. Morris practices at United Theranostics – Chesapeake/Glen Burnie, located at:

331 Oak Manor Drive, Suite 201,
Glen Burnie, MD 21061

Phone:(443)333-1894 


Website: www.unitedtheranostics.com

Dr. Michael A. Morris’s career is a testament to his unwavering commitment to advancing medical science and improving patient outcomes. Through his leadership at United Theranostics, extensive research contributions, and dedication to education, he continues to shape the future of nuclear medicine and radiopharmaceutical therapy.

U.S. News Health